SS28 is an orally bioavailable analog of SRT501 with potent antitumor activity; it inhibits tubulin polymerization, induces G2/M phase cell cycle arrest, and triggers apoptosis rather than necrosis in cancer cells. It demonstrates significant cytotoxicity against various cancer cell lines, including CEM, A549, SUDHL8, Molt4, Reh, Nalm6, HeLa, and 293T cells, with IC50 values ranging from 2.6 to 21 μM. In vivo, oral administration of SS28 (15 mg/kg body weight, every other day for 9 doses) effectively inhibits tumor cell proliferation and halts tumor progression in Ehrlich Ascites Carcinoma (EAC)-bearing BALB/c mice.